西妥珠单抗

西妥珠单抗(英语:cirmtuzumab;开发代号:UC-961),或译次妥珠单抗,是一种抗ROR1人源化单克隆抗体[1][2]

西妥珠单抗
单克隆抗体
种类?
目标ROR1
临床资料
其他名称UC-961
法律规范状态
法律规范
  • 研究性
识别信息
CAS号1643432-38-5  checkY
UNII

它是一种处于早期临床试验中的实验药物,用于治疗包括慢性淋巴细胞白血病(CLL)在内的多种癌症。[3][4]

参考资料

  1. ^ Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts. Blood. 2015, 126 (23): 1736 [2024-03-10]. doi:10.1182/blood.V126.23.1736.1736. (原始内容存档于2019-09-13). 
  2. ^ Researchers to test novel drug combination against toughest breast cancers. Medical Express. 2018-08-27 [2024-03-10]. (原始内容存档于2023-04-06). 
  3. ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
  4. ^ 1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo. Lymphoma News Today. 2018-05-18 [2024-03-10]. (原始内容存档于2023-04-07).